Form 4 for KYNB KYNTRA BIO, INC.
Accepted 2025-07-02 00:00:00 ET · period of report 2025-06-30 · accession 0001415889-25-019067 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-07-02 | 2025-06-30 | KYNB | Schoeneck James A | Dir | P - Purchase | $5.07 | +23.6K | 39.7K | +146% | +$119.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-30 | P | A | 23,567 | $5.07 | 39,666 | I By Trust | — | — | (F1) Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $4.935 to $5.25. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. (F2) Reflects a 1-for-25 reverse stock split effective on June 16, 2025. |